Breast Cancer Clinical Trial
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Summary
Expanded access for participants with cancer with RET activation who are ineligible for an ongoing selpercatinib (also known as LOXO-292) clinical trial or have other considerations that prevent access to selpercatinib through an existing clinical trial.
The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.
Full Description
N/A for expanded access
Eligibility Criteria
Inclusion Criteria:
Diagnosis of cancer with RET activation, who are not eligible for an ongoing selpercatinib clinical trial and are medically suitable for treatment with selpercatinib
Have progressed or are intolerant to standard therapy, or no standard therapy option exists, or in the opinion of the investigator, are unlikely to derive significant clinical benefit from standard therapy
Have adequate organ function
Exclusion Criteria:
Currently enrolled in an ongoing clinical study of selpercatinib or another RET inhibitor
Clinically significant active cardiovascular disease or history of myocardial infarction within 6 months prior to study treatment; ongoing cardiomyopathy; or current prolongation of the QT interval corrected for heart rate using Fridericia's formula (QTcF) interval greater than 470 milliseconds
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 63 Locations for this study
Goodyear Arizona, 85338, United States More Info
Principal Investigator
Scottsdale Arizona, 85259, United States More Info
Principal Investigator
Duarte California, 91010, United States More Info
Principal Investigator
Los Angeles California, 90095, United States More Info
Principal Investigator
Orange California, 92868, United States More Info
Principal Investigator
Sacramento California, 95814, United States More Info
Principal Investigator
San Diego California, 92103, United States More Info
Principal Investigator
San Francisco California, 94115, United States More Info
Principal Investigator
San Francisco California, 94115, United States More Info
Principal Investigator
San Francisco California, 94115, United States More Info
Principal Investigator
Santa Clara California, 95051, United States More Info
Principal Investigator
Vallejo California, 94589, United States More Info
Principal Investigator
Hollywood Florida, 33021, United States More Info
Principal Investigator
Jacksonville Florida, 32224, United States More Info
Principal Investigator
Orlando Florida, 32803, United States More Info
Principal Investigator
Tallahassee Florida, 32308, United States More Info
Principal Investigator
Athens Georgia, 30607, United States More Info
Principal Investigator
Atlanta Georgia, 30329, United States More Info
Principal Investigator
Chicago Illinois, 60637, United States More Info
Principal Investigator
Zion Illinois, 60099, United States More Info
Principal Investigator
Boston Massachusetts, 02114, United States More Info
Principal Investigator
Boston Massachusetts, 02215, United States More Info
Principal Investigator
Ann Arbor Michigan, 48109, United States More Info
Principal Investigator
Grand Rapids Michigan, 49546, United States More Info
Principal Investigator
Rochester Minnesota, 55905, United States More Info
Principal Investigator
Las Vegas Nevada, 89169, United States More Info
Principal Investigator
New York New York, 10065, United States More Info
Principal Investigator
Cleveland Ohio, 44195, United States More Info
Principal Investigator
Columbus Ohio, 43210, United States More Info
Principal Investigator
Tulsa Oklahoma, 74133, United States More Info
Principal Investigator
Philadelphia Pennsylvania, 19104, United States More Info
Principal Investigator
Philadelphia Pennsylvania, 19124, United States More Info
Principal Investigator
Houston Texas, 77030, United States More Info
Principal Investigator
Houston Texas, 77030, United States More Info
Principal Investigator
Fairfax Virginia, 22031, United States More Info
Principal Investigator
Madison Wisconsin, 53792, United States More Info
Principal Investigator
Camperdown New South Wales, 2050, Australia More Info
Principal Investigator
St. Leonards New South Wales, 2065, Australia More Info
Principal Investigator
Chermside Queensland, 4032, Australia More Info
Principal Investigator
Melbourne Victoria, 3000, Australia More Info
Principal Investigator
Nedlands Western Australia, 6009, Australia More Info
Principal Investigator
Bordeaux Aquitaine, 33076, France More Info
Principal Investigator
Würzburg Bayern, 97080, Germany More Info
Principal Investigator
Köln Nordrhein-Westfalen, 50937, Germany More Info
Principal Investigator
Hong Kong Shatin, New Territories, , Hong Kong More Info
Principal Investigator
Jerusalem Yerushalayim, 91031, Israel More Info
Principal Investigator
Beer-Sheva , 84101, Israel More Info
Principal Investigator
Milano Lombardie, 20133, Italy More Info
Principal Investigator
Pisa PI, 56124, Italy More Info
Principal Investigator
Milano , 20162, Italy More Info
Principal Investigator
Kashiwa Chiba, 277-8, Japan More Info
Principal Investigator
Sapporo Hokkaido, 060-8, Japan More Info
Principal Investigator
Kanazawa Ishikawa, 920-8, Japan More Info
Principal Investigator
Chuo-ku Tokyo, 104-0, Japan More Info
Principal Investigator
Yonago Tottori, 683-8, Japan More Info
Principal Investigator
Gdansk , 80-95, Poland More Info
Principal Investigator
Warszawa , 02-03, Poland More Info
Principal Investigator
Madrid , 28050, Spain More Info
Principal Investigator
How clear is this clinincal trial information?